| 11/9/2018 | BKCAHY | S&P affirms Bausch Health
|
| 11/7/2018 | CAHYLM | Bausch Health tenders, solicits consents for 7½% notes due 2021
|
| 8/23/2018 | BKCADDHY | Moody’s ups Bausch SGL, changes view
|
| 6/1/2018 | CAHYLM | Valeant to redeem 5 3/8%, 6 3/8%, 6¾%, 7¼% senior notes on July 2
|
| 5/17/2018 | CAHY | New Issue: Valeant prices $750 million 8.6-year notes at par to yield 8½%
|
| 5/17/2018 | BKCADDHY | Moody’s rates Valeant notes Caa1
|
| 5/17/2018 | CAHY | Valeant talks $750 million 8.6-year notes to yield in 8 5/8% area; pricing Thursday
|
| 5/17/2018 | CAHY | Valeant debt refinancing to include $750 million new 8.6-year notes coming in Thursday drive-by
|
| 5/15/2018 | BKCAHY | Moody’s rates Valeant loans Ba3
|
| 5/14/2018 | BKCAHY | S&P rates Valeant loans BB-, notes B-
|
| 5/10/2018 | CAHY | Valeant Pharmaceuticals refinancing to include $750 million secured, $750 million unsecured notes
|
| 5/8/2018 | BKBWCAHYLM | Valeant cuts debt by $6.9 billion since 2016; ‘more work to be done’
|
| 4/12/2018 | CAHYLM | Valeant plans to redeem $150 million 6 3/8% senior notes on May 14
|
| 4/10/2018 | CAHYLM | Valeant Pharmaceuticals wraps tender offers for three series of notes
|
| 3/26/2018 | CAHYLM | Valeant receives early tenders for $1.45 billion notes, to buy all
|
| 3/12/2018 | CAHYLM | Valeant, unit up tender for 6 3/8%, 5 3/8%, 6¾% notes to $1.5 billion
|
| 3/12/2018 | CAHY | New Issue: Valeant prices upsized $1.5 billion 9¼% eight-year notes at par
|
| 3/12/2018 | BKCAHY | Fitch gives B-/RR4 to Valeant notes
|
| 3/12/2018 | BKCAHY | Moody’s rates Valeant notes Caa1
|
| 3/12/2018 | CAHY | Valeant to sell $1.25 billion eight-year notes in Monday drive-by; whisper is 9¼%-9½% area
|
| 3/12/2018 | CAHYLM | Valeant, unit tender for $1.25 billion of 6 3/8%, 5 3/8%, 6¾% notes
|
| 3/6/2018 | BKCAHY | Fitch rates Valeant, facility, notes
|
| 2/28/2018 | BKBWCAHY | Valeant cuts debt to $25.5 billion; further debt cuts planned in 2018
|
| 2/28/2018 | CAHYLM | Valeant Pharmaceuticals calls $71 million 7% senior notes due 2020
|
| 12/4/2017 | CAHYLM | Valeant offers to buy back up to $1.5 billion 7%, 6 3/8%, 5 3/8% notes
|
| 12/4/2017 | BKCAHY | S&P rates Valeant Pharmaceuticals notes B-
|
| 12/4/2017 | BKCADDHY | Moody’s gives Valeant notes Caa1
|
| 12/4/2017 | CAHY | New Issue: Valeant sells upsized $1.5 billion 9% senior notes due 2025 at 98.611 to yield 9¼%
|
| 12/4/2017 | CAHY | Valeant to price $1 billion eight-year notes in Monday drive-by
|
| 12/4/2017 | CAHYLM | Valeant, unit begin month-long tender for $1 billion of three issues
|
| 11/14/2017 | CAHY | New Issue: Valeant Pharmaceuticals sells $750 million tap of 5½% secured notes due 2025 at par
|
| 11/14/2017 | CAHY | Valeant Pharmaceuticals talks $750 million tap of 5½% notes at par; pricing Tuesday
|
| 11/13/2017 | CAHY | Valeant to price $750 million tap of 5½% secured notes due 2025; pricing expected Tuesday
|
| 11/8/2017 | BKCADDHY | Moody’s revises Valeant to stable
|
| 10/16/2017 | CAHYLM | Valeant tenders for $1 billion notes oversubscribed at early deadline
|
| 10/2/2017 | CAHY | New Issue: Valeant sells $1 billion eight-year secured notes at par to yield 5½%
|
| 10/2/2017 | BKCAHY | S&P rates Valeant notes BB-
|
| 10/2/2017 | BKCAHY | Moody’s gives Valeant notes Ba3
|
| 10/2/2017 | CAHY | Valeant to price $1 billion eight-year secured notes on Monday backing tender offer
|
| 10/2/2017 | CAHYLM | Valeant Pharmaceuticals tenders for $1 billion of three note series
|
| 7/13/2017 | CAHYLM | Valeant to call $500 million of 6¾% notes due 2018 on Thursday
|
| 6/9/2017 | BWCAHY | Valeant seeks to cut, but not eliminate, debt from capital structure
|
| 3/30/2017 | BKCADDHY | Moody’s ups Valeant to SGL-2
|
| 3/21/2017 | CAHYLM | Valeant accepts 70.9% of tendered 6¾% notes in oversubscribed offer
|
| 3/10/2017 | CAHYLM | Valeant lifts tender offer cap for 6¾% notes due 2018 to $1.1 billion
|
| 3/9/2017 | CAHY | New Issue: Valeant prices upsized to $3.25 billion secured notes in two tranches
|
| 3/9/2017 | BKCAHY | S&P provides BB- to Valeant notes
|
| 3/9/2017 | CAHY | Valeant to sell $2.5 billion secured notes in two parts on Thursday
|
| 3/7/2017 | CAHYLM | Valeant begins tender offer for up to $600 million 6¾% notes due 2018
|
| 3/6/2017 | BKCAHY | Moody’s rates Valeant facilities, notes Ba3
|
| 3/6/2017 | CAHY | Valeant plans new debt securities as part of debt refinancing
|
| 11/15/2016 | BKBWCADDHYLM | Valeant aims to pay $5 billion of $30 billion debt via asset sales
|
| 11/8/2016 | BKCADDHY | Moody’s lowers Valeant, facilities, debt
|
| 8/18/2016 | BKCAHY | Valeant lenders OK amendment permitting loan paydown with notes
|
| 8/10/2016 | BKCAHY | Moody’s: Valeant unchanged by amendment
|
| 8/10/2016 | BKCAHY | Valeant launches amendment to permit loan paydown with senior notes
|
| 8/9/2016 | BKBWCAHYLM | Valeant says debt-cutting remains a focus, $880 million cut since Q1, seeks covenant relief
|
| 6/10/2016 | BKCAHY | Moody’s ups Valeant liquidity
|
| 6/3/2016 | CADDHY | Valeant again triggers note defaults for holdup in filing financials
|
| 5/19/2016 | CADDHY | Valeant Pharmaceuticals gets default notice after delay filing 10-Q
|
| 4/25/2016 | CADDHY | Valeant Pharmaceuticals defaults on notes after delay filing 10-K
|
| 4/13/2016 | BKCADDHY | Moody’s drops Valeant liquidity to SGL-4
|
| 3/31/2016 | BKCAHY | Moody’s drops Valeant, debt
|
| 3/16/2016 | BKCAHY | S&P: Valeant on negative watch
|
| 3/16/2016 | BKCAHY | Moody’s lowers Valeant, loans, notes
|
| 3/15/2016 | BKBWCAHY | Valeant in covenant compliance now but faces reporting breaches; ‘comfortable’ with liquidity
|
| 3/15/2016 | BKCADDHY | Valeant delays 10-K, breaching covenants and opening door to default
|
| 2/29/2016 | BKCAHY | Moody’s reviews Valeant
|
| 2/23/2016 | BKCAHY | Moody’s changes Valeant to negative
|
| 12/16/2015 | BKCAHY | Valeant updates on guidance, aims to chop leverage to 4.0 times area
|
| 10/27/2015 | BKCAHY | S&P revises Valeant to negative
|
| 10/26/2015 | BKCAHY | Valeant forms ad hoc committee to address Philidor concerns, CEO blasts ‘false’ report
|
| 10/20/2015 | BKCAHY | Moody’s changes Valeant view to stable
|
| 4/1/2015 | CAHYLM | Valeant to redeem Salix’s 6% senior notes due 2021 in two stages
|
| 3/13/2015 | CAHY | New Issue: Valeant prices upsized $10 billion equivalent of notes in four parts
|
| 3/12/2015 | CAHY | Valeant Pharmaceuticals upsizes four-part bond deal to $10 billion, downsizes bank loan
|
| 3/12/2015 | CAHY | Valeant talks $9.6 billion equivalent four-part notes offering; commitments due 5 p.m. ET Thursday
|
| 3/10/2015 | BKCAHY | Moody's rates Valeant loans Ba1, notes B1
|
| 3/10/2015 | BKCAHY | S&P provides B to Valeant notes
|
| 3/9/2015 | BKCAHY | S&P gives BB to Valeant loans
|
| 2/23/2015 | BKCAHY | Valeant plans $15.15 billion of term loans and notes for Salix buy
|
| 1/15/2015 | CAHY | New Issue: Valeant Pharmaceuticals prices $1 billion eight-year notes at par to yield 5½%
|
| 1/15/2015 | BKCAHY | Moody’s rates Valeant notes B1, view positive
|
| 1/15/2015 | CAHYLM | Valeant Pharmaceuticals calls $499.58 million 6 7/8% notes in full
|
| 1/15/2015 | CAHY | Valeant Pharmaceuticals to price $1 billion eight-year notes Thursday
|
| 1/8/2015 | BKBWCAHYLMLW | Valeant cuts leverage to 3.5x, holds out prospect of more debt paydowns
|
| 11/21/2014 | BKCAHY | Moody’s revises Valeant to stable
|
| 11/15/2013 | CAHY | New Issue: Valeant Pharmaceuticals sells upsized $900 million 5 5/8% eight-year notes at par
|
| 11/15/2013 | CAHY | Valeant Pharmaceuticals selling $850 million eight-year senior notes in Friday drive-by
|
| 6/25/2013 | CAHY | Valeant sets price talk for restructured $3.2 billion two-part deal
|
| 6/19/2013 | CAHY | Valeant Pharmaceuticals plans roadshow for $3.2 billion two-part notes
|
| 2/12/2013 | BKCAHY | S&P rates Valeant loans BBB-
|
| 1/4/2013 | BKCAHY | Valeant Pharmaceuticals targets revenue of up to $4.8 billion, 35% increase in EPS for 2013
|
| 11/19/2012 | CAHYLM | Valeant buys back C$89.9 million three senior note series at discount
|
| 9/24/2012 | CA | Market Commentary: CIBC, Agrium sell U.S. dollar deals; Golden Credit Card to tap U.S., Canadian markets
|
| 9/20/2012 | CA | Market Commentary: Quebec sells C$500 million 10-year add-on, Ontario, Valeant focus deal action in U.S. markets
|
| 9/20/2012 | CAHY | Valeant restructures $2.25 billion notes offer, sets price talk
|
| 9/19/2012 | CAHY | Valeant Pharmaceuticals intends to price $2.25 billion of notes in three parts on Thursday
|
| 9/19/2012 | CAHY | Valeant Pharmaceuticals selling $2.25 billion of notes in three parts
|
| 9/19/2012 | CA | Market Commentary: Canada Housing, Sherritt tap mortgage bond, junk markets; Ontario dollar deal 'expensive'
|
| 9/13/2012 | BKCAHY | Moody's rates Valeant loan Ba1, notes B1
|
| 9/7/2012 | BKCAHY | S&P rates Valeant loan BBB-, notes BB-
|
| 9/7/2012 | BKCAHY | Valeant's acquisition of Medicis expected to generate $1.75 billion bonds, $1 billion term loan
|
| 9/5/2012 | BKCAHY | S&P affirms Valeant
|
| 9/4/2012 | BKCAHY | Moody's could cut Valeant
|
| 9/4/2012 | CA | Market Commentary: BMO taps U.S. market; Canadian deals forecast; BMO, TransCanada tighten, Valeant flat
|
| 6/29/2012 | BKCAHY | S&P rates Valeant loan BBB-
|
| 6/5/2012 | BKCACVHY | S&P rates Valeant loan BBB-
|
| 6/5/2012 | BKCAHY | Moody's says Valeant debt is credit negative
|
| 1/31/2012 | BKCAHY | S&P rates Valeant loan BBB-
|
| 1/30/2012 | BKCACVHY | Moody's rates Valeant loan Ba1
|
| 1/6/2012 | BKCAHY | Valeant gives cash flow guidance of roughly $1.2 billion for 2012
|
| 11/3/2011 | CACVHYLM | Valeant Pharmaceuticals reports double-digit growth, ends Q3 with $5.6 billion of debt
|
| 11/3/2011 | CACVHYLM | Valeant resumes buyback program for convertibles, notes and other debt
|
| 9/28/2011 | BKCAHY | S&P ups Valeant, rates loans
|
| 9/28/2011 | BKCAHY | Moody's: Valeant notes Baa3
|
| 9/15/2011 | CACVHYLM | Valeant eyes growth in Europe; cash flow from operations could hit $900 million in 2012
|
| 8/29/2011 | CACVHYLM | Valeant increases securities repurchase program to C$1.8 billion
|
| 5/26/2011 | BKCAHY | S&P affirms Valeant
|
| 5/9/2011 | CA | Market Commentary: Thompson Creek Metals to sell notes; Savanna Energy plans roadshow; Valeant, Nortel better
|
| 3/30/2011 | BKCACVHY | Moody's may cut Valeant
|
| 3/30/2011 | BKCACVHY | S&P puts Valeant on watch
|
| 3/2/2011 | CA | Market Commentary: Bank of Montreal, Valeant Pharmaceuticals, Nova Scotia tap domestic, U.S. bond markets
|
| 3/2/2011 | CAHY | Valeant sets talk on $1.5 billion two-part offering of senior notes
|
| 11/19/2010 | BKCACVHY | Moody's: Valeant unchanged
|
| 11/4/2010 | CACVHYLM | Valeant to buy back $1.5 billion convertibles, senior notes, stock
|
| 9/21/2010 | CAHY | New Issue: Valeant upsizes to $1.2 billion, prices seven-, 10-year senior notes
|
| 9/21/2010 | CA | Market Commentary: Canadian bonds turn higher on Fed plans; Quebec bonds narrow; Valeant sells $1.2 billion
|
| 9/17/2010 | CAHY | Valeant Pharmaceuticals sets talk for $1 billion two-part note sale
|
| 9/9/2010 | CAHY | Valeant to start roadshow Wednesday for $1 billion senior notes
|
